Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
301P - Changes in lipid-levels following aromatase inhibitor treatment in early postmenopausal breast cancer
Presenter: Marie Lund
Session: Poster session 14
302P - Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey
Presenter: Matteo Lambertini
Session: Poster session 14
303P - Predicting quality of life trajectories in young women with breast cancer: 5-year results from a large prospective cohort
Presenter: Bryan Vaca-Cartagena
Session: Poster session 14
304P - Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study
Presenter: Shinsuke Sasada
Session: Poster session 14
306P - Patient-reported symptoms in early breast cancer and future cardiovascular events: A province-wide administrative database study
Presenter: Edith Pituskin
Session: Poster session 14
307P - Exposure to Di-2-ethylhexyl phthalate and breast cancer incidence: A cohort study
Presenter: Lijuan Tang
Session: Poster session 14
308P - Impact of the COVID-19 (C19) pandemic on breast cancer (BC) treatment patterns in the US
Presenter: Mariana Chavez Mac Gregor
Session: Poster session 14
310P - Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer
Presenter: Sonya Reid
Session: Poster session 14
311P - Optimizing breast cancer staging: Redefining tumor size classification using big data analytics
Presenter: Bin Feng
Session: Poster session 14